Future Of British Business
Covid Shielders Keep Isolating as Astra’s New Drug Hits Hurdles
- UK company seeks to get back to forefront of Covid-19 fight
- Evusheld antibody sales up but forecasts still conservative
Evusheld
Photographer: Jonathan Nackstrand/AFP/Getty Images
This article is for subscribers only.
Well over a year after the rollout of Covid-19 vaccines allowed most people to return to life as usual, Mark Oakley is still hiding away in a summer house in his garden, avoiding contact with even his closest family members.
He’s had five vaccine doses, but the protective effect has been suppressed by medication he’s taking to tame a lung disorder. He thinks his predicament could be helped with Evusheld, an AstraZeneca Plc drug that protects vulnerable people from Covid by injecting them with two antibodies, but he can’t get hold of it.